Influence of Baseline Demographics Disease Characteristics on Efficacy of an Oral Selective TYK2 Inhibitor, BMS-986165, in Patients With Moderate to Severe Plaque Psoriasis: Phase 2, Randomized, Placebo-Controlled Trial. J of Skin 2019, 3, S14. https://doi.org/10.25251/skin.3.supp.14.